NorthStar Medical Radioisotopes Expands Management Team with Appointment of Jean-Noel David, MBA, MS, as Vice President, Operations

NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for therapeutic and medical imaging applications, has announced the appointment of Jean-Noel David, MBA, MS, as Vice President, Operations. In this new position, he brings more than 20 years of operational and leadership expertise in the pharmaceutical and life sciences industry to the Company. Mr. David will have company-wide responsibility for Engineering, Manufacturing and Project Management, and report to President and Chief Operating Officer Frank Scholz, Ph.D.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230418005138/en/

NorthStar Medical Radioisotopes has expanded its management team with the appointment of Jean-Noel David, MBA, MS, as Vice President, Operations. (Photo: Business Wire)

“NorthStar continues to rapidly expand and advance our programs for therapeutic and diagnostic radioisotopes and radiopharmaceuticals, as well as our new Radiopharmaceutical CDMO/CMO services unit,” said Dr. Scholz. “We’re excited to welcome Jean-Noel to NorthStar. His depth of experience, industry knowledge and demonstrated success in leading development programs and operations will be great assets as we continue to grow across the Company and provide meaningful solutions that can make a positive difference in patients’ lives.“

“It’s a great pleasure and opportunity to join NorthStar in this dynamic stage of its development,” said Mr. David. “I’m eager to apply my operations and engineering expertise to help drive the company forward, and look forward to working with this talented team in advancing innovative technologies that can significantly benefit U.S. and global healthcare.”

Prior to joining NorthStar, Mr. David was Vice President, Transformation and Network Optimization, Cell Gene Therapy, at Catalent, where he oversaw transformation of its Gene Therapy supply chain network. Previous to Catalent, he was Managing Director, North America, with SEQENS CDMO, a global leader in pharmaceutical solutions (CDMO, Generic APIs). Prior to SEQENS, he spent more than eight years with ThermoFisher, Pharma Group and Patheon in roles of increasing responsibility, where he was most recently Senior Director Business Transformation, Patheon. During his tenure with ThermoFisher and Patheon, he led strategic projects related to the integration of ThermoFisher CDMO operations, oversaw the transformation of Patheon’s Biologics unit and led integration efforts for a number of acquisitions. Previous to that, he was a senior management consultant with IBM, and Implementation Director for the Government of Dubai. Mr. David holds an MBA from Emory Business School, Atlanta, Ga. and an MS in Mechanical Engineering from Ecole National Superieure Techniques Avancees, Paris, France.

About NorthStar Medical Radioisotopes, LLC

NorthStar Medical Radioisotopes is a commercial-stage nuclear medicine company focused on advancing patient care by providing diagnostic and therapeutic radioisotopes, novel radiopharmaceuticals and customized radiopharmaceutical development services. Its proven management team and state-of-the-art, environmentally preferable and non-uranium based technologies have made it an emerging leader at the forefront of U.S. medical radioisotope and radiopharmaceutical production. NorthStar’s molybdenum-99 (Mo-99) program is the sole source of domestic Mo-99, used to generate the standard-of-care diagnostic imaging radioisotope for assessing heart disease and cancer. It is expanding its industry-leading position in the growing area of therapeutic radioisotopes, used in targeted radiopharmaceutical therapy to treat cancer and other serious diseases, and is poised to be the first commercial-scale producer of non-carrier added (n.c.a.) actinium-225 (Ac-225) and copper-67 (Cu-67). NorthStar’s Radiopharmaceutical Contract Development and Manufacturing Organization (CDMO/CMO) services unit will provide customized service offerings and specialized radiopharmaceutical expertise to help biopharmaceutical companies rapidly advance their development and commercialization programs. For more information about NorthStar’s comprehensive portfolio and patient-focused services, visit: www.northstarnm.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230418005138/en/